Cara Therapeutics reported $34.66M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US USD 161.58M 6.63M
Acelrx Pharmaceuticals ACRX:US USD 7.14M 7M
Cara Therapeutics CARA:US USD 34.66M 7.18M
Chugai Pharma 4519:JP JPY 128.4B 7.28B
Depomed DEPO:US USD 27.78M 3.44M
Endo International Ordinary Shares ENDP:US USD 1.18B 1.13B
Halozyme Therapeutics HALO:US USD 128.4M 10.09M
Horizon Pharma HZNP:US USD 764.75M 23.1M
Johnson & Johnson JNJ:US USD 19.51B 1.54B
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Pacira Pharmaceuticals PCRX:US USD 146.18M 8M
Pain Therapeutics PTIE:US USD 21.34M 1.43M
Pfizer PFE:US USD 13.23B 2.41B
Revance Therapeutics RVNC:US USD 106.5M 20.29M
Supernus Pharmaceuticals SUPN:US USD 178.88M 20.17M
Teva Pharmaceutical Industries TEVA:US USD 3.18B 1.56B
Vanda Pharmaceuticals VNDA:US USD 61.41M 481K